• Secondary analysis from a European, cross-sectional, multicenter study of 1410 patients diagnosed with Major Depressive Disorder (MDD).
• Patients were categorized based on first-line antidepressant: trazodone (≥150 mg/day, once-daily) or other agents.
• Comparison of socio-demographic, clinical, and treatment characteristics between groups.
• Use of statistical methods including chi-square tests, ANCOVAs, and post-hoc logistic regression analyses.

Dr. Anna M. Laure is a medical doctor who graduated from the Medical University of Vienna in 2024 and is currently in postgraduate clinical training with a focus on psychiatry and psychotherapy. She has gained clinical experience through rotations in Austria, Germany, and Tanzania. Dr. Laure has contributed to research within the Group for the Study of Resistant Depression (GSRD), focusing on real-world treatment strategies in major depressive disorder (MDD), and was previously involved in the CoviKET working group, focusing on the clinical evaluation of Long COVID. An abstract based on her research was published in Neuroscience Applied and presented at the ECNP Congress 2024. She also reviews for the International Journal of Psychiatry in Clinical Practice and was awarded the 2024 ÖGPB Prize for Clinical Psychiatry.